Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function
Príomhchruthaitheoirí: | Chapman, K, Pavord, I, Paggiaro, P, Sciurba, F, Bafadhel, M, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S |
---|---|
Formáid: | Conference item |
Foilsithe / Cruthaithe: |
American Thoracic Society
2018
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
de réir: Bafadhel, M, et al.
Foilsithe / Cruthaithe: (2018) -
Mepolizumab for eosinophilic COPD
de réir: Sciurba, F, et al.
Foilsithe / Cruthaithe: (2018) -
Mepolizumab for eosinophilic chronic obstructive pulmonary disease
de réir: Pavord, I, et al.
Foilsithe / Cruthaithe: (2017) -
Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
de réir: Pavord, I, et al.
Foilsithe / Cruthaithe: (2017) -
Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
de réir: Gunsoy, N, et al.
Foilsithe / Cruthaithe: (2017)